LexGo

CJEU rules that free samples of OTC medicinal products can be provided to pharmacists
15/06/2020

 

On 11 June 2020, the Court of Justice of the European Union (CJEU) confirmed that it is prohibited to distribute free samples of prescription-only medicines to pharmacists but clarified – against the Advocate General's opinion of 20 January 2020 – that the prohibition does not extend to over-the-counter (OTC) products. 

Background

Before the German courts, Novartis successfully objected to the supply by Ratiopharm of free samples of a generic version of Novartis' Voltaren Schmerzgel (a pain relief gel with the active ingredient diclofenac) to pharmacists "for demonstration purposes". Ratiopharm appealed to the Bundesgerichtshof, which submitted a request for a preliminary ruling based on Article 96 of Directive (EU) No 2001/83/EC relating to medicinal products for human use (hereinafter the "Directive"). This provision permits, under strict conditions, the supply of free samples of medicinal products to persons qualified to prescribe them, i.e. physicians. In short, the Bundesgerichtshof asked the CJEU whether the supply of free samples under Article 96 of the Directive extends to pharmacists.

Distinction between prescription-only and OTC medicinal products 

Article 96(1) of the Directive sets out the conditions under which samples of medicinal products can be provided to "persons qualified to prescribe medicinal products" (limitation on the number of samples, only upon written request, subject to an adequate system of control and accountability and an obligatory summary of product characteristics). Article 96(2) authorises the Member States to adopt more restrictive measures in this regard.

The CJEU confirmed that Article 96 cannot be interpreted as authorising the supply of free samples of medicinal products to pharmacists, since they do not belong to the category of "persons qualified to prescribe medicinal products".

However, the CJEU went on to find that Article 96(1) applies to prescription-only medicinal products, which are potentially dangerous and whose use requires supervision by a physician, not to all medicinal products. Article 96(2) must be read in conjunction with Article 96(1) and has the same scope. Consequently, it relates only to medicinal products requiring a prescription.

In its interpretation, the CJEU relied on the Directive's distinction between OTC and prescription-only medicinal products, including the impact of this distinction on the possibility to advertise the products. Prescription-only medicines give rise to certain risks in relation to their use or effects and require supervision by persons qualified to prescribe them. Over-the-counter medicinal products, on the other hand, are not associated with the same risks. The CJEU mentioned Recital 51, which states that, under certain restrictive conditions, it should be possible to provide samples of medicinal products free of charge to persons qualified to prescribe (i.e. physicians) or supply (i.e. pharmacists) them, so that they can familiarize themselves with new products and acquire experience in dealing with them.

These considerations led to the conclusion that the Directive allows the supply of free samples of medicinal products to pharmacists under national law, subject to strict conditions in keeping with the Directive's purpose and provided the products concerned do not require a prescription.

Application to Belgium: Royal Decree of 11 January 1993

In Belgium, the Royal Decree of 11 January 1993 restricts the supply of free samples of medicinal products to persons qualified to prescribe them and hospital pharmacies (Article 1 in conjunction with Articles 2 and 5).

As the CJEU ruled that national law cannot prohibit the supply to pharmacists of free samples of OTC medicinal products, Belgian law will have to be amended to allow for this possibility.

Voir aussi : Nautadutilh Avocats Luxembourg Sàrl ( Mr. Vincent Wellens )

[+ http://www.nautadutilh.com]


Click here to see the ad(s)
Tous les articles Droit Européen

Derniers articles Droit Européen

Digital platforms – The gatekeepers under the EU’s new Digital Markets Act
18/01/2021

In December last year the European Commission published its much anticipated draft Digital Markets Act. 

Digital platforms – The gatekeepers under the EU’s new Digital Markets Act Read more

Brexit: European Union Trademarks – Situation as from 1 January 2021
11/12/2020

The United Kingdom (“UK”) left the European Union (“EU”) on 31 January 2020 and Brexit’s tra...

Brexit: European Union Trademarks – Situation as from 1 January 2021 Read more

Regulatory certainty for the investment fund industry in view of the forthcoming end of the trans...
10/12/2020

In view of the departure of the United Kingdom from the EU on 1 February 2020 and the forthcoming end of the transitional ...

Read more

CJEU: new developments in the realm of VAT recovery on dead deal costs
20/11/2020

In the context of a prospective acquisition of shares in a company in the telecommunications sector, and with the intentio...

Read more

Derniers articles de Mr. Vincent Wellens

The Sky Is Not the Limit: Space Activities in Luxembourg
15/02/2021

At the end of 2020, Luxembourg adopted the Act of 15 December 2020 on space activities (loi du 15 décembre 2020 por...

Read more

Adoption of New Secondment Act
18/12/2020

On 9 December 2020, the Luxembourg Parliament adopted a new secondment act, the purpose of which is to transpose into nati...

Read more

Finally some practical EDPB guidance on how to make international data transfers lawful
13/11/2020

After a long, four-month wait, we finally have recommendations from the European Data Protection Board (EDPB) on “su...

Read more

The Court of Justice of the EU clarifies the assessment of position marks for services
15/10/2020

The Court of Justice of the EU recently clarified the criteria to take into account when assessing the distinctive charact...

Read more

LexGO Network